News · Regeneron Pharmaceuticals, Inc. (REGN) · Healthcare

Regeneron jumps after Q3 beat; shares rise 13.3%

Session of October 30, 2026 · Published November 1, 2026 · 4 min read

What happened

Regeneron (REGN) rose 13.3% on October 30, 2026, because third-quarter results beat estimates and showed revenue gains driven by Dupixent, Eylea HD and Libtayo. The stock opened 6.2% above the previous close and finished at $927.89 on trading volume 4.5 times its 20-day average. The S&P 500 fell 1.8% that day and the healthcare sector median fell 2.3%, so the stock outperformed both the market and its sector.

Closing price over the last 30 trading sessions. On October 30, 2026, REGN closed at $927.89, up 13.3% on the day and 16.3% higher than 30 sessions earlier.

How big was the move

The day's change amounted to 5.7 times a typical daily move for this stock, making it a pronounced company-specific reaction to the earnings release. Over the last five sessions the stock rose 15.3% while the S&P 500 fell 0.6%. Compared with its sector, the stock was 15.6 percentage points better than the sector median on the day. Market sensitivity remained muted, with a beta of 0.48, indicating the stock tends to move less than the market.

Each bar is one day's price change; the outlined bar is October 30, 2026. A typical daily move over the past year was 1.9%, so the latest move equals 6.9 times that. Moves outside the dashed lines (about 3.9%) are unusual.

The technical picture

The stock traded 17.6% above its 20-day moving average and 17.0% above its 50-day moving average, while it was 25.8% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 19 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) was 79, above 70, a level often called overbought.

Closing price over the past year. REGN ends the period at its 52-week high, above its 50-day average ($793.30) and above its 200-day average ($737.54).

Shares sat 0.8% below the 52-week high. Over one month the stock rose 26.3% and over three months it rose 22.2%. One year performance showed the stock rose 42.1%, which is 32.1 percentage points ahead of the S&P 500. Volatility was also elevated, at 37% annualized over 60 days, higher than 85% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, Regeneron reported revenue of $16.90 billion, which grew 18.6% from a year earlier, and diluted earnings per share of $45.26, which rose 8.4% from a year earlier. Gross margin was 85.8% compared with 85.4% a year earlier, and operating margin was 29.5% versus 25.9% a year earlier. Free-cash-flow margin stood at 21.2% and return on invested capital was 9.2%.

Quarterly revenue by period end. The latest quarter brought $5.1B, 36.3% more than the same quarter a year earlier.

The company held net cash of $952.1 million, and share count over one year decreased by 1.5%. Valuation metrics showed a price to trailing earnings of 20.5 times trailing earnings and a price to forward earnings of 15.6 times expected earnings. The price to trailing earnings level is higher than 76% of its own readings over the past five years, with a five-year median of 18.6 times earnings. Free-cash-flow yield was 4.3% in the latest period.

PromtFinance scores within the sector painted a mixed but generally positive picture. Value scored 76 (Positive), Quality 86 (Strong) and Momentum 82 (Strong), balanced by Growth 57 (Neutral) and Revisions 59 (Neutral). Stability also scored 86 (Strong), underscoring solid financial durability even as the stock trades toward the richer end of its historical valuation band.

Earnings and analyst expectations

Regeneron reported on October 30, 2026, earnings per share of $20.07 against $16.51 expected, 21.6% above estimates. The company has beaten estimates in six consecutive quarters and the average surprise over the last four reports was 18.8% above estimates. Typical two-day reactions after recent reports have been more modest, with the stock rising 3.0% on average, making the current 13.3% move substantially larger than recent post-earnings responses. The next scheduled report is January 29, 2027.

Diluted earnings per share by quarter. The latest quarter shows $18.45, against $13.62 in the same quarter a year earlier.

News outlets highlighted that the quarter was driven by strong sales for Dupixent, Eylea HD and Libtayo. Dupixent global quarterly net sales were $6.5 billion, up 35% year over year. Separately, total revenue for the cited period rose 36% year over year to $5.1 billion, according to Seeking Alpha and Zacks Investment Research. Those product trends were central to the beat and helped explain the outsized market reaction on October 30.

What to watch

Next report: January 29, 2027.
Consensus price target: $856.80, 7.7% below the closing price; 49 analysts cover the stock with a consensus rating of Buy.
PromtFinance scores: Quality 86 (Strong), Momentum 82 (Strong), Value 76 (Positive).
Valuation: Price to trailing earnings 20.5 times trailing earnings; price to forward earnings 15.6 times expected earnings.
Technical volatility: 37% annualized over 60 days, higher than 85% of its own readings over five years.

Full REGN analysis: scores, chart and financials →